Ipsen is global biotechnology specialty care company. Co. engages in research, development, manufacture and sale of pharmaceutical products for human healthcare. Co.'s product portfolio includes pharmaceutical products marketed around the world to specialists working in its targeted therapeutic areas (oncology, endocrinology, neurology and haematology). These products are specialist care drugs. Co. also markets products in other therapeutic areas including gastroenterology, cardiovascular and cognitive disorders. These products are primary care drugs. Co.'s brand names include Decapeptyl®, Somatuline®, Dysport®, Nutropin Aq®, Smecta®, Forlax®, Nisis®,Adrovance®, Exforge® and Adenuric®.
  • TickerIPN
  • ISINFR0010259150
  • ExchangeEuronext Paris
  • SectorPharmaceuticals & Biotechnology
  • CountryFrance
Bruno Cavalier ...
  • Jerôme Bodin

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/21/2020

...

Bruno Cavalier ...
  • Jerôme Bodin

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 21/09/2020

Alors que Peugeot et FCA viennent de clore le débat autour des termes financiers de leur rapprochement, le fondamental devrait, enfin, revenir au premier plan à quelques mois de la naissance de Stellantis. Or, le potentiel de la nouvelle entité nous semble encore largement sous-estimé et la valorisation très faible, faisant de Peugeot et FCA aujourd’hui, Stellantis demain, les meilleures opportunités boursières sur le secteur. Nous réitérons nos opinions Achat et relevons nos OC à res...

Eric Le Berrigaud

IPSEN - BUY TOP PICKS | EUR103(+9%) CHECKMATE-9ER confirms high hopes for Cabometyx in 1L mRCC

IPSEN - BUY TOP PICKS | EUR103(+9%) CHECKMATE-9ER confirms high hopes for Cabometyx in 1L mRCC Data presented at ESMO 2020 were as good as hoped Efficacy-wise, Cabo-Nivo is competitive, with an advantage on PFS Like PFS, safety and QoL were more emphasized than we expected Combinations are becoming SoC in 1L mRCC and cabo-nivo looks like a preferred one

Christophe-Raphaël Ganet ...
  • Thomas Renaud

Ipsen : CheckMate9ER trial Cabometyx+Opdivo: promising data – TP target price increased: € 100 vs € 91

>Interesting efficacy and survival data - At the ESMO (European Society for Medical Oncology) conference, Ipsen announced the results of its phase III CheckMate 9ER pivotal trial in which Cabometyx® (cabozantinib) in combination with BMS’s Opdivo® (nivolumab) showed significant improvements across all the efficacy endpoints (in particular overall survival) in patients with previously untreated advanced renal cell carcinoma (RCC). The trial was a randomised, multinatio...

Christophe-Raphaël Ganet ...
  • Thomas Renaud

Ipsen : Etude CheckMate9ER Cabometyx+Opdivo : données prometteuses – OC relevé: 100 € vs 91 €

>Des données d’efficacité et de survie, intéressantes - Lors du congrès ESMO (European Society for Medical Oncology), Ipsen a annoncé les résultats de son étude pivotale de Phase III CheckMate 9ER dans laquelle Cabometyx® (cabozantinib) en combinaison avec Opdivo® (nivolumab) de BMS, démontrant des améliorations significatives sur tous les critères d’efficacité (en particulier la survie globale), chez des patients atteints d’un carcinome du rein avancé (RCC) non trait...

Jérôme VINERIER

Short term view - IPSEN : Falling prices.

The trend is bearish. Prices are falling again, but the movement has become hesitant. The next support is at €116.00. The bearish trend would be challenged above €142.10.

Jérôme VINERIER

Analyse court terme - IPSEN : Les prix baissent.

La tendance est baissière. Les prix baissent à nouveau, mais le mouvement est devenu hésitant. Le prochain support est à 116,00 €. La tendance baissière serait remise en cause au-dessus de 142,10 €.

Jérôme VINERIER

Short term view - IPSEN : The trend is bearish.

The trend is bearish. The movement goes on. The next target is at €116.00, then €103.90. Passing €142.10 would question the continuation of the fall.

Jérôme VINERIER

Analyse court terme - IPSEN : La tendance est baissière.

La tendance est baissière. Le mouvement se poursuit. Le prochain objectif est à 116,00 €, puis 103,90 €. Le franchissement de 142,10 € remettrait en cause la suite de la baisse.

Jérôme VINERIER

Analyse moyen terme - IPSEN : La baisse récente gagne en vigueur.

La tendance est haussière. La baisse récente gagne en vigueur. Le prochain support est à 115,64 €. La tendance serait remise en cause par la rupture de 96,60 €.

Eric Le Berrigaud

Ipsen: Exelixis’ Q2 figures: Cabometyx continues to grow, with plus and minus

Brief Comment - Ipsen: (BUY, Fair Value EUR150 (+6%)) Exelixis’ Q2 figures: Cabometyx continues to grow, with plus and minus

Eric Le Berrigaud

IPSEN - BUY TOP PICKS | EUR103(+9%) CHECKMATE-9ER confirms high hopes for Cabometyx in 1L mRCC

IPSEN - BUY TOP PICKS | EUR103(+9%) CHECKMATE-9ER confirms high hopes for Cabometyx in 1L mRCC Data presented at ESMO 2020 were as good as hoped Efficacy-wise, Cabo-Nivo is competitive, with an advantage on PFS Like PFS, safety and QoL were more emphasized than we expected Combinations are becoming SoC in 1L mRCC and cabo-nivo looks like a preferred one

Christophe-Raphaël Ganet ...
  • Thomas Renaud

Ipsen : CheckMate9ER trial Cabometyx+Opdivo: promising data – TP target price increased: € 100 vs € 91

>Interesting efficacy and survival data - At the ESMO (European Society for Medical Oncology) conference, Ipsen announced the results of its phase III CheckMate 9ER pivotal trial in which Cabometyx® (cabozantinib) in combination with BMS’s Opdivo® (nivolumab) showed significant improvements across all the efficacy endpoints (in particular overall survival) in patients with previously untreated advanced renal cell carcinoma (RCC). The trial was a randomised, multinatio...

Christophe-Raphaël Ganet ...
  • Thomas Renaud

Ipsen : Etude CheckMate9ER Cabometyx+Opdivo : données prometteuses – OC relevé: 100 € vs 91 €

>Des données d’efficacité et de survie, intéressantes - Lors du congrès ESMO (European Society for Medical Oncology), Ipsen a annoncé les résultats de son étude pivotale de Phase III CheckMate 9ER dans laquelle Cabometyx® (cabozantinib) en combinaison avec Opdivo® (nivolumab) de BMS, démontrant des améliorations significatives sur tous les critères d’efficacité (en particulier la survie globale), chez des patients atteints d’un carcinome du rein avancé (RCC) non trait...

Eric Le Berrigaud

IPSEN: Contact - Adjusting our numbers | BUY TOP PICKS | EUR98 vs. EUR97 (+13%)

IPSEN - BUY TOP PICKS | EUR98 vs. EUR97 (+13%) Contact - Adjusting our numbers The new CEO is assessing the situation Palovarotene is back on the regulatory agenda Cabometyx confirmed as a key growth driver with a but Modest change to our FV – BUY Top Pick confirmed

Christophe-Raphaël Ganet

Ipsen : Confident but cautious tone – Forecasts and target price revised up

>Main elements: news flow still positive - We note the following items in particular:1- The fall in Q2 sales of Decapeptyl® (15% of sales), Dysport® (13%) and OTC seem to clearly come from the impact of COVID-19 and lockdown (fewer consultations and closure of medical centres). Ipsen notes a slow improvement since June-July, even if China seems to be resuming fairly slowly in relation to Europe.Moreover, while the diagnosis of NET new patients has decreased,...

Maxime Kogge

Ipsen : Still a low-risk credit despite growing dependence on Somatuline. Buy reiterated

We are reviewing Ipsen's latest results. In a difficult environment, the group performed well, even though its latest earnings attest to the widening gap between the impressive performance of Somatuline, the group's blockbuster, and the lacklustre showing of other products. A large-scale acquisition is undoubtedly on the group's agenda, but it should not jeopardise the group's credit profile before the bond matures in 2023. - >Somatuline, the group's blockbuster, continues...

Maxime Kogge

Ipsen : Malgré la dépendance croissante à Somatuline, la credit story reste peu risquée. Achat réitéré

Nous refaisons le point à l'occasion des derniers résultats semestriels d'Ipsen. Dans un contexte difficile, le groupe a performé correctement même si la dernière publication témoigne un peu plus du décalage entre la performance impressionnante de Somatuline, le blockbuster du groupe, et celle en demi-teinte des autres produits. Une acquisition d'ampleur est sans doute à l'agenda mais elle ne devrait pas remettre en cause le profil de crédit d’Ipsen à l'horizon de la maturité de ...

Marnik Hinnekens

TP ICAP - Europe - Morning CreditUpdate 24/10/2019 - Intrum, Ford - FR

Intrum (Achat) - 9M-19 : EBIT de SEK4,2 mds (€391m, +41,1%) Ford (Achat) : Abaisse ses perspectives pour 2019 Scor (Achat) - 9M-19 : Primes brutes de €12,1 mds (+3,2% à tcc) SEB (Achat) - 9M-19 : Résultat d’exploitation de SEK17,8 mds (€1,7 md, +4,8%) Constellium (Achat) : Revoit à la baisse ses objectifs 2019 Edenred (Achat) : Vise une croissance organique d’EBITDA >10% jusqu’à 2022 Europcar (Vente vs Achat) : Abaisse ses perspectives pour 2019 Schmolz + Bickenbach : Prévoit une augmentation de capital de CHF189m à CHF350m ...

Maxime Kogge

Ipsen : Un rendement faible mais suffisant vu le profil de risque équilibré. Achat confirmé sur l’obligation 2023

L’obligation Ipsen a connu un parcours satisfaisant depuis l’émission en 2016. La prime de 70bps sur les obligations BBB à l’émission s’est nettement resserrée jusqu’à fin 2018 dans un contexte d’aversion au risque. Toutefois, l’obligation affiche de nouveau depuis le début de l’année une prime de l’ordre de 40bps. Le newsflow a en effet été mitigé au S1 avec 1/ l’annonce de l’acquisition de Clementia, une opération prometteuse à long terme mais pénalisante à court terme sur les ...

Maxime Kogge

Ipsen : Low but sufficient yield in light of balanced risk profile. Buy confirmed on 2023 bond

The bond has seen a satisfactory track record since its 2016 issuance. The 70bp spread premium on the JPM 'BBB' index vs. the bond issue in June 2016 narrowed significantly until the end of 2018. However, the bond has anew offered a spread premium of around 40bps year to date. The newsflow was mixed with 1/ the announcement of the Clementia acquisition on 25 February, a promising deal in the long term but detrimental for ratios in the short term; 2/ an increase in the generic thr...

Bruno Cavalier ...
  • Jerôme Bodin

ODDO BHF SECURITIES MORNING NEWS – DETAILED COMMENTS 09/21/2020

...

Bruno Cavalier ...
  • Jerôme Bodin

ODDO BHF SECURITIES MORNING NEWS – COMMENTAIRES DETAILLES 21/09/2020

Alors que Peugeot et FCA viennent de clore le débat autour des termes financiers de leur rapprochement, le fondamental devrait, enfin, revenir au premier plan à quelques mois de la naissance de Stellantis. Or, le potentiel de la nouvelle entité nous semble encore largement sous-estimé et la valorisation très faible, faisant de Peugeot et FCA aujourd’hui, Stellantis demain, les meilleures opportunités boursières sur le secteur. Nous réitérons nos opinions Achat et relevons nos OC à res...

Despite a better risk assessment and improving to Neutral, IPSEN SA remains under pressure

IPSEN SA (FR), a company active in the Pharmaceuticals industry, improves its market behaviour and slightly increases its general evaluation. The independent financial analyst theScreener just upgraded the stock market behaviour as moderately risky. At a fundamental level, theScreener confirms 1 out of 4 possible stars; the general evaluation is slightly increased to Neutral but the title remains under pressure. As of the analysis date October 8, 2019, the closing price was EUR 85.10 and its target price was estimated at EUR 76.36.

Ford Equity International Rating and Forecast Report

Ford Equity International Research Reports cover 60 countries with over 30,000 stocks traded on international exchanges. A proprietary quantitative system compares each company to its peers on proven measures of business value, growth characteristics, and investor behavior. Ford's three recommendation ratings buy, hold and sell, represent each stock’s return potential relative to its own country market.. The rating reports which are generated each week, include the fundamental details behind each recommendation and reflect the fundamental and price data as of the last trading day of the we...

Expert Corporate Governance Service (ECGS)

Ipsen – AGM 29 May 2020

Governance   On 18 December 2019, Ipsen announced that David Meek has resigned as the company's CEO and will step down from the Board of Directors, effective 31 December 2019. The Board has decided to appoint Aymeric Le Chatelier, currently CFO as Interim CEO to replace David Meek as of 1 January 2020. The Board has asked the Nominations Committee, chaired by Carol Xueref, to conduct a search process in order to identify the future CEO. Remuneration   As a result of his resignation, David Meek lost his rights to the 2018 and 2019 LTIP and to the supplementary defined benefit pension, but ...

Ipsen - Assemblée générale des actionnaires du 28 mai 2019

Le conseil n'est pas majoritairement composé de membres libres de conflits d'intérêts. Par conséquent, parmi les renouvellements proposés, seul le Président du conseil sera soutenu en raison de la séparation des fonctions avec la Direction Générale (résolutions 5 à 7). En ce qui concerne la rémunération 2018 du Directeur Général, l'absence de communication des taux de réalisation de chacun des critères financiers du bonus constitue un manque rédhibitoire pour Proxinvest. Par ailleurs, l'attribution d'actions gratuites est basée sur des critères non vérifiables et qui sont calculés sur une pér...

Expert Corporate Governance Service (ECGS)

Ipsen -AGM and EGM 28 May 2019

The majority of the Board is not composed of independent members. Consequently, among the proposed renewals, only the Chairman of the Board will be supported due to the separation of functions with the Executive Management (resolutions 5 to 7). With regard to the 2018 remuneration of the CEO, the failure to communicate the achievement rates of each of the financial criteria related to the bonus constitutes a fundamental flaw for ECGS. In addition, the allocation of performance shares is based on criteria that cannot be verified and are calculated over a period of only two years, which is insu...

Ipsen – Proxinvest Corporate Governance Rating ® : C

Proxinvest Corporate Governance Rating ® helps investors integrate governance into their investment decision and identify governance risks and opportunities within their portfolio. Proxinvest Corporate Governance Rating ® Service rates European issuers through the analysis of four main themes : Ownership & Shareholder rights, Board & Committees, Audit & Process, Remuneration. Each theme is rated taking into account several comprehensive sub-categories. Our unique two-step process to achieve each rating includes a first step quantitative valuation and a second step qualitative filter...

SRI Quantitative KPIs

Les analyses Gaïa sont des analyses ESG (Environnement, Social, Gouvernance) dediees aux entreprises de tailles intermediaires (PME, ETI) françaises. Elles presentent 120 indicateurs quantitatifs sur les trois derniers exercices.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch